Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3415515 | 0.85 | GRM5 (0.38) | CLK1MLYCDHTR7HTR1ADRD2 | |
| SCHEMBL22204222 | 0.84 | CLK1 (0.40) | CLK1HTR7HTR1ADRD2HTR2A | |
| SCHEMBL22204210 | 0.84 | CLK1 (0.40) | CLK1HTR7HTR1ADRD2HTR2A | |
| SCHEMBL22204207 | 0.84 | CLK1 (0.40) | CLK1HTR7HTR1ADRD2HTR2A | |
| SCHEMBL6482424 | 0.81 | RAB9A (0.40) | MLYCDGRM5 | |
| SCHEMBL17804225 | 0.81 | CLK1 (0.40) | CLK1HTR7HTR1ADRD2HTR2A | |
| SCHEMBL1400663 | 0.81 | CLK1 (0.40) | CLK1HTR7HTR1ADRD2HTR2A | |
| SCHEMBL6484238 | 0.81 | MLYCD (0.34) | MLYCD | |
| SCHEMBL6482760 | 0.80 | MLYCD (0.33) | MLYCDMMP9 | |
| SCHEMBL10691214 | 0.77 | ACACB (0.33) | MLYCDMMP9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6469172-B2 | 2-AMINO-6-((4-AMINOPIPERIDIN-1-YL)METHYL)PYRIDINE; CHEMICAL INTERMEDIATE FOR MUSCARINIC M3 RECEPTOR ANTAGONISTS; ACYLATION OF 2-AMINO-6-BROMOPYRIDINE WITH TRIMETHYLACETIC ACID | MERCK & CO., INC. | 2002-10-22 | — | — | US | claimed |
| US-20010051727-A1 | Process for the preparation of chemical compounds | MERCK& CO., INC. | 2001-12-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051727-A1 | Process for the preparation of chemical compounds | CHRM3, CHRM5, CHRM2 | CLK1 3865/4885MLYCD 1839/4885HTR7 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.